Term
| For guidance on Precision medicine use.... |
|
Definition
|
|
Term
| Voriconazole substrate of |
|
Definition
|
|
Term
| CPIC recommended VORICONAZOLE for Tx of |
|
Definition
-1st line>>Aspergillosis
-Alt Tx for candidemia |
|
|
Term
CYP2C19 Inhibitors
CYP2C19 Inducer |
|
Definition
CYP2C19 Inhibitors:
-Fluvox,Flucon, PPIs
CYP2C19 Inducer: Rifampin |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| CYP2C19 Normal Metabolizer |
|
Definition
*1/*1
[Use regular dose]
Intermediate metab=*1/*2, *1/*3
[Use regular dose] |
|
|
Term
| CYP2C19 Ultrarapid Metabolizer |
|
Definition
*17/*17
[Choose alt agent] |
|
|
Term
| CYP2C19 rapid Metabolizer |
|
Definition
|
|
Term
|
Definition
*2/*2,*2/*3, *3/*3
[Choose alt agent] |
|
|
Term
| Most poor metabolizers (race) |
|
Definition
|
|
Term
| MOST ULTRA METABOLIZERS (RACE) |
|
Definition
|
|
Term
Subtherapeutic doses if: ______
Increased conc if:_______ |
|
Definition
Subtherapeutic doses if: UM
Increased conc if: PM |
|
|
Term
| Tacrolimus is substrate for |
|
Definition
CYP3A4
-Narrow therapeutic index drug |
|
|
Term
CYP3A4 Inhibitors:
CYP3A4 Inducers: |
|
Definition
CYP3A4 Inhibitors:Ketoconazole,ritonavir, verapamil
CYP3A4 Inducers:Rifampin, St. johns wart |
|
|
Term
| CYP3A5 can be major contributor to CYP3A activity if |
|
Definition
| CYP3A5*1 allele is present |
|
|
Term
| CYP3A5 Extensive metabolizer |
|
Definition
*1/*1
[inc starting dose tacrolimus] |
|
|
Term
| CYP3A5 Intermediate metabolizer |
|
Definition
*1/*3, *1/*6, *1/*7
[inc starting dose tacrolimus] |
|
|
Term
|
Definition
*3/*3, 6/6, 7/7 3/6 etc
[use regular starting dose tacrolimus] |
|
|
Term
| CYP3A5 most seen in (Race) |
|
Definition
|
|
